Thomas Yau

Thomas Yau

University of Hong Kong - Pok Fu Lam / Hong Kong
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 411676
香港大學
person_outline Thomas Yau's MOST POPULAR ARTICLES
1-) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.CAL Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V ...N Engl J Med. 382, 1894-1905, 20203520*2020
2-) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ...The Lancet 389 (10088), 2492-2502, 201735022017
3-) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trialRS Finn, BY Ryoo, P Merle, M Bouattour, HY Lim, V Breder, J Edeline, ...8832020
4-) Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trialT Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ...JAMA oncology 6 (11), e204564-e204564, 202010842020
5-) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised …J Li, S Qin, R Xu, TCC Yau, B Ma, H Pan, J Xu, Y Bai, Y Chi, L Wang, ...The lancet oncology 16 (6), 619-629, 20158592015